

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal642cxy

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 APR 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 APR 09 ZDB will be removed from STN
NEWS 5 APR 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDS
NEWS 6 APR 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 APR 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 APR 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 JUN 03 New e-mail delivery for search results now available
NEWS 10 JUN 10 MEDLINE Reload
NEWS 11 JUN 10 PCTFULL has been reloaded
NEWS 12 JUL 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 JUL 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 JUL 29 Enhanced polymer searching in REGISTRY
NEWS 15 JUL 30 NETFIRST to be removed from STN
NEWS 16 AUG 08 CANCERLIT reload
NEWS 17 AUG 08 PHARMAMarketLetter (PHARMAML) - new on STN
NEWS 18 AUG 08 NTIS has been reloaded and enhanced
NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d.
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 16:33:54 ON 08 AUG 2002

=> file medline, biosis, cancerlit, uspatfull
COST IN U.S. DOLLARS
FULL ESTIMATED COST
SINCE FILE ENTRY TOTAL
0.21 0.21 SESSION

FILE 'MEDLINE' ENTERED AT 16:34:22 ON 08 AUG 2002

FILE 'BIOSIS' ENTERED AT 16:34:22 ON 08 AUG 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'CANCERLIT' ENTERED AT 16:34:22 ON 08 AUG 2002

FILE 'USPATFULL' ENTERED AT 16:34:22 ON 08 AUG 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s her2 or neu (a) oncogene and antibody?

L1 4330 HER2 OR NEU (A) ONCOGENE AND ANTIBOD?

=> dup rem l1
PROCESSING IS APPROXIMATELY 55% COMPLETE FOR L1
PROCESSING COMPLETED FOR L1
L2 2797 DUP REM L1 (1533 DUPLICATES REMOVED)

=> s l2 and treat?

L3 1413 L2 AND TREAT?

=> s l3 not PY=>1990

L4 8 L3 NOT PY=>1990

=> d l4 1-8

L4 ANSWER 1 OF 8 MEDLINE

AN 89283246 MEDLINE

DN 89283246 PubMed ID: 2566965

TI Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185.

AU McKenzie S J; Marks P J; Lam T; Morgan J; Panicali D L; Trimpe K L; Carney W P

CS Applied biotechnology, Cambridge, Massachusetts 02142.

SO ONCOGENE. (1989 May) 4 (5) 543-8.

Journal code: 8711562. ISSN: 0950-9232.

CY ENGLAND: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 198907

ED Entered STN: 19900309

Last Updated on STN: 20000303

Entered Medline: 19890706

ANSWER 2 OF 8 MEDLINE

AN 88176036 MEDLINE

DN 88176036 PubMed ID: 2451200

TI Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo.

AU Drebin J A; Link V C; Greene M I

CS Immunology, Department of Pathology and Laboratory Medicine, University of Pennsylvania, School of Medicine, Philadelphia 19104.

SO ONCOGENE. (1988 Mar) 2 (3) 273-7.

Journal code: 8711562. ISSN: 0950-9232.

CY ENGLAND: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 198805

ED Entered STN: 19900308

Last Updated on STN: 19900308

Entered Medline: 19880505

ANSWER 3 OF 8 MEDLINE
 AN 87067463 MEDLINE
 DN 87067463 PubMed ID: 3466178
 TI Inhibition of tumor growth by a monoclonal antibody reactive
 with an oncogene-encoded tumor antigen.
 AU Drebin J A; Link V C; Weinberg R A; Greene M I
 SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
 AMERICA. (1986 Dec) 83 (23) 9129-33.
 Journal code: 7505876. ISSN: 0027-8424.
 United States
 CY Journal; Article; (JOURNAL ARTICLE)
 DT English
 LA English
 FS Priority Journals
 EM 198701
 ED Entered STN: 19900302
 Last Updated on STN: 19900302
 Entered Medline: 19870114

ANSWER 4 OF 8 MEDLINE
 AN 85228220 MEDLINE
 DN 85228220 PubMed ID: 2860972
 TI Down-modulation of an oncogene protein product and reversion of the
 transformed phenotype by monoclonal antibodies.
 AU Drebin J A; Link V C; Stern D F; Weinberg R A; Greene M I
 NC 5-T32-GM07753 (NIGMS)
 CA-014732 (NCI)
 SO CELL. (1985 Jul) 41 (3) 697-706.
 Journal code: 0413066. ISSN: 0032-8674.
 United States
 CY Journal; Article; (JOURNAL ARTICLE)
 DT English
 LA English
 FS Priority Journals
 EM 198507
 ED Entered STN: 19900320
 Last Updated on STN: 20000303
 Entered Medline: 19850731

ANSWER 5 OF 8 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1985:417683 BIOSIS
 DN B80:87675
 TI DOWN-MODULATION OF AN ONCOGENE PROTEIN PRODUCT AND REVERSION OF THE
 TRANSFORMED PHENOTYPE BY MONOCLONAL ANTIBODIES.
 AU DREBIN J A; LINK V C; STERN D F; WEINBERG R A; GREENE M I
 CS DEP. PATHOL., HARVARD MED. SCH., BOSTON, MASS. 02115.
 SO CELL. (1985) 41 (3): 695-706.
 CODEN: CELLS5. ISSN: 0092-8674.
 FS BA: OLD
 LA English

ANSWER 6 OF 8 CANCERLIT
 AN 89647882 CANCERLIT
 DN 89647882
 TI EFFECTS OF MONOCLONAL ANTIBODIES REACTIVE WITH THE NEU
 ONCOGENE PRODUCT ON THE NEOPLASTIC PROPERTIES OF NEU-TRANSFORMED
 CELLS.
 AU Drebin J A
 CS Harvard Univ., MA.
 SO Disa Abstr Int [B]. (1988) 48 (11) 3243.
 ISSN: 0419-4217.
 (THESIS)
 DT English
 LA English
 FS Institute for Cell and Developmental Biology

Entered Medline: 198812
 ED Entered STN: 19941107
 Last Updated on STN: 19941107

ANSWER 7 OF 8 CANCERLIT
 AN 86627483 CANCERLIT
 DN 86627483
 TI THE NEU ONCOGENE ENCODES A CELL SURFACE PROTEIN WITH
 PROPERTIES OF A GROWTH FACTOR RECEPTOR.
 AU Stern D F; Schechter A; Vaidyanathan L; Weinberg R; Breene M; Drebin J
 CS Whitehead Inst. for Biomedical Res., Massachusetts Inst. of Technology,
 Cambridge, MA.
 SO Bristol-Myers Cancer Symp. (1985) 7 165-70.
 DT (MEETING PAPER)
 LA English
 FS Institute for Cell and Developmental Biology
 EM 198612
 ED Entered STN: 19941107
 Last Updated on STN: 19941107

ANSWER 8 OF 8 USPTAFULL
 AN 89:45576 USPTAFULL
 TI Therapy using glucosidase processing inhibitors
 Rohrschneider, Larry R., 1501 - 1st Ave. N., #3A, Mercer Island, WA,
 United States
 PA Nichols, Everett J., 1501 - 1st Ave. N., #3A, Seattle, WA, United States
 98109
 Fred Hutchinson Cancer Research Center, Seattle, WA, United States (U.S.
 corporation)
 PI Nichols, Everett J., Seattle, WA, United States (U.S. individual)
 AI US 4837237 19890606
 DT US 1985-753686 19850709 (6)
 FS Utility
 FS Granted
 LN CNT 1284
 INCL INCLM: 514/062.000
 INCLS: 514/023.000; 514/283.000; 514/345.000; 514/729.000; 514/738.000;
 436/063.000; 436/084.000
 NCL INCLM: 514/062.000
 NCLS: 436/063.000; 436/064.000; 514/023.000; 514/283.000; 514/345.000;
 514/729.000; 514/738.000
 IC [4]
 ICM: A61K031-70
 ICS: G01N033-48
 EXP 424/85; 514/283; 514/345; 514/729; 514/738; 514/62; 514/23; 435/172.2;
 435/200; 435/207; 435/208; 435/240.2; 436/63; 436/64
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his
 (FILE 'HOME' ENTERED AT 16:33:54 ON 08 AUG 2002)
 FILE 'MEDLINE, BIOSIS, CANCERLIT, USPTAFULL' ENTERED AT 16:34:22 ON 08
 AUG 2002
 L1 4330 S HER2 OR NEU (A) ONCOGENE AND ANTIBOD?
 L2 2797 DUP REM L1 (1533 DUPLICATES REMOVED)
 L3 1413 S L2 AND TREAT?
 L4 8 S L3 NOT FY=>1990
 => s 11 and cancer
 L5 3233 L1 AND CANCER
 => s 15 and admin?

L6		1065 L5 AND ADMIN?	
=>	dub rem l6		
L7		PROCESSING COMPLETED FOR L6	
		930 DUP REM L6 (135 DUPLICATES REMOVED)	
=>	s l7 not py=>1990		
L8		5 L7 NOT PY=>1990	
=>	d 1-5 l8		
L8		ANSWER 1 OF 5 MEDLINE	
AN		88176036 MEDLINE	
DN		88176036 Pubmed ID: 2451200	
TI		Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo.	
AU		Drebin J A; Link V C; Greene M I	
CS		Immunology, Department of Pathology and Laboratory Medicine, University of Pennsylvania, School of Medicine, Philadelphia 19104.	
SO		ONCOGENE, (1988 Mar) 2 (3) 273-7.	
CY		Journal code: 8711562. ISSN: 0950-9232.	
LA		ENGLAND; United Kingdom	
DT		Journal; Article; (JOURNAL ARTICLE)	
LA		English	
FS		Priority Journals	
EM		198805	
ED		Entered STN: 19900308	
		Last Updated on STN: 19900308	
		Entered Medline: 19880505	
L8		ANSWER 2 OF 5 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.	
AN		1988:264811 BIOSIS	
DN		BA86:4055	
TI		MONOCLONAL ANTIBODIES SPECIFIC FOR THE NEU	
AU		ONCOGENE PRODUCT DIRECTLY MEDIATE ANTI-TUMOR EFFECTS IN-VIVO.	
CS		DREBIN J A; LINK V C; GREENE M I	
SO		DIV. IMMUNOL., DEP. PATHOL., UNIV. PA. SCH. MED., PHILADELPHIA, PA. 19104.	
		ONCOGENE, (1988) 2 (4), 387-394.	
		CODEN: ONCNE5. ISSN: 0950-9232.	
FS		BA; OLD	
LA		English	
L8		ANSWER 3 OF 5 CANCERLIT	
AN		91662231 CANCERLIT	
DN		91662231	
TI		IMMUNE SYSTEM AND CANCER.	
AU		Anonymous	
CS		No affiliation given.	
SO		Non-serial, (1989) Immune System and Cancer. Tokyo, 1988. Hamaoka T et al, eds. Philadelphia, Taylor and Francis, 347 p., 1989.	
DT		Book; (MONOGRAPH)	
LA		English	
FS		Institute for Cell and Developmental Biology	
EM		199103	
ED		Entered STN: 19941107	
		Last Updated on STN: 19970509	
L8		ANSWER 4 OF 5 CANCERLIT	
AN		89647882 CANCERLIT	
DN		89647882	
TI		EFFECTS OF MONOCLONAL ANTIBODIES REACTIVE WITH THE NEU	
AU		ONCOGENE PRODUCT ON THE NEOPLASTIC PROPERTIES OF NEU-TRANSFORMED	
CS		CELLS.	
L6		1065 L5 AND ADMIN?	
=>	dub rem l6		
L7		PROCESSING COMPLETED FOR L6	
		930 DUP REM L6 (135 DUPLICATES REMOVED)	
=>	s l7 not py=>1990		
L8		5 L7 NOT PY=>1990	
=>	d 1-5 l8		
L8		ANSWER 1 OF 5 USPATFULL	
AN		89:45576 USPATFULL	
TI		Therapy using glucosidase processing inhibitors	
IN		Rohrschneider, Larry R., 1501 - 1st Ave. N., #3A, Mercer Island, WA, United States	
		Nichols, Everett J., 1501 - 1st Ave. N., #3A, Seattle, WA, United States	
PA		98109 Fred Hutchinson Cancer Research Center, Seattle, WA, United States (U.S. corporation)	
PI		Nichols, Everett J., Seattle, WA, United States (U.S. individual)	
AI		US 4837237 19890606	
DI		US 1985-753686 19850709 (6)	
DT		Utility	
FS		Granted	
LN,CNT		1284	
INCL		INCLM: 514/062.000	
		INCLS: 514/023.000; 514/283.000; 514/345.000; 514/729.000; 514/738.000; 436/063.000; 436/064.000	
NCL		NCLM: 514/062.000	
		NCLS: 436/063.000; 436/064.000; 514/023.000; 514/283.000; 514/345.000; 514/729.000; 514/738.000	
IC		[4]	
		ICM: A6LK031-70	
		ICS: CO1N033-48	
EXF		424/85; 514/283; 514/345; 514/729; 514/738; 514/62; 514/23; 435/172.2; 435/200; 435/207; 435/208; 435/240.2; 436/63; 436/64	
		CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
=>	d l8 4 all		
L8		ANSWER 4 OF 5 CANCERLIT	
AN		89647882 CANCERLIT	
DN		89647882	
TI		EFFECTS OF MONOCLONAL ANTIBODIES REACTIVE WITH THE NEU	
		ONCOGENE PRODUCT ON THE NEOPLASTIC PROPERTIES OF NEU-TRANSFORMED	
		CELLS.	
AU		Drebin J A	
CS		Harvard Univ., MA.	
SO		Dis Abstr Int [B], (1988) 48 (11) 3243.	
		ISSN: 0419-4217.	
DT		(THESIS)	
LA		English	
FS		Institute for Cell and Developmental Biology	
EM		198812	
ED		Entered STN: 19941107	
		Last Updated on STN: 19941107	
AB		Recent studies have demonstrated the existence of specific genes, termed oncogenes, which may play a role in the etiology of cancer. The isolated from a rat neuroblastoma, which has been termed neu. Initially new oncogene encodes a 185,000 dalton protein product, termed p185. A panel of monoclonal antibodies has been produced cells.	

which reacts with domains of the p185 molecule that are expressed on the surface of murine cells transformed by an activated rat neu oncogene. These antibodies do not bind murine cells transformed by various other agents. There is significant antibody reactivity with the rat neuroblastomas from which activated neu genes have been obtained; these antibodies also react with a protein on nontransformed rat fibroblasts that appears to be the normal rat homolog of the p185 molecule encoded by the activated neu oncogene. Exposure of neu-transformed cells to p185-specific monoclonal antibodies in vitro results in the rapid and reversible loss of cell-surface and total cellular p185. Although not directly cytotoxic, exposure to anti-p185 monoclonal antibodies also causes neu-transformed cells to revert to a nontransformed phenotype, as determined by the capacity for anchorage-independent growth. This with great likelihood results from antibody-mediated down-modulation of cell-surface p185. Thus, the p185 molecule plays an important role in maintenance of the transformed phenotype. In vivo treatment with any of several p185-specific monoclonal antibodies is able to significantly inhibit the tumorigenic growth of neu-transformed cells implanted into nude mice and syngeneic rats. Furthermore, treatment with mixtures of monoclonal antibodies reactive with distinct domains of the p185 molecule results in synergistic antitumor effects and eradication of small tumor burdens in some animals. The administration of monoclonal antibodies reactive with cell-surface domains of an oncogene-encoded protein represents a novel and potentially efficacious approach to the therapy of neoplasia. (Full text available from University Microfilms International, Ann Arbor, MI, as Order No: AAD88-00768)

CN 0 (proto-oncogene protein p185 (neu); 0 (Antibodies, Monoclonal); 0 (Proto-Oncogene Proteins))

=> d his

(FILE 'HOME' ENTERED AT 16:33:54 ON 08 AUG 2002)

FILE 'MEDLINE, BIOSIS, CANCERLIT, USPATFULL' ENTERED AT 16:34:22 ON 08 AUG 2002

L1 4330 S HER2 OR NEU (A) ONCOGENE AND ANTIBOD?
L2 2797 DUP REM L1 (1533 DUPLICATES REMOVED)
L3 1413 S L2 AND TREAT?
L4 8 S L3 NOT PY->1990
L5 3233 S L1 AND CANCER
L6 1065 S L5 AND ADMIN?
L7 930 DUP REM L6 (135 DUPLICATES REMOVED)
L8 5 S L7 NOT PY->1990

=> s 16 and subcut?
L9 579 L6 AND SUBCUT?

=> s 19 and concentration (s) antibod?
L10 339 L9 AND CONCENTRATION (S) ANTIBOD?

=> dup rem l10
PROCESSING COMPLETED FOR L10
L11 339 DUP REM L10 (0 DUPLICATES REMOVED)

=> s l11 not py->1995
L12 1 L11 NOT PY->1995

=> d l12 1 all